{
    "id": "114cd6ad-9203-4034-b390-3e0901e064a4",
    "indications": "welireg hypoxia-inducible factor inhibitor indicated : von hippel-lindau ( vhl ) disease treatment adult patients von hippel-lindau ( vhl ) disease require therapy associated renal cell carcinoma ( rcc ) , central nervous system ( cns ) hemangioblastomas , pancreatic neuroendocrine tumors ( pnet ) , requiring immediate surgery . ( 1.1 ) advanced renal cell carcinoma ( rcc ) treatment adult patients advanced renal cell carcinoma ( rcc ) clear cell component following programmed death receptor-1 ( pd-1 ) programmed death-ligand 1 ( pd-l1 ) inhibitor vascular endothelial growth factor tyrosine kinase inhibitor ( vegf-tki ) . ( 1.2 ) pheochromocytoma paraganglioma ( ppgl ) treatment adult pediatric patients 12 years older locally advanced , unresectable , metastatic pheochromocytoma paraganglioma ( ppgl ) . ( 1.3 )",
    "contraindications": "recommended welireg adult patients 120 mg administered orally daily without food . ( 2.1 ) recommended welireg pediatric patients 12 years older based bodyweight : patients weighing ≥ 40 kg : 120 mg orally daily patients weighing < 40 kg : 80 mg orally daily",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "BELZUTIFAN",
            "code": "7K28NB895L"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S)",
            "code": "6N003M473W"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Merck Sharp & Dohme LLC",
    "name": "WELIREG",
    "effectiveTime": "20250514",
    "indications_original": "WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).   ( 1.3 )",
    "contraindications_original": "The recommended dosage of WELIREG in adult patients is 120 mg administered orally once daily with or without food. ( 2.1 ) The recommended dosage of WELIREG in pediatric patients 12 years and older is based on bodyweight: Patients weighing ≥ 40 kg: 120 mg orally once daily Patients weighing < 40 kg: 80 mg orally once daily",
    "adverseReactions_original": "None."
}